Literature DB >> 10516127

The head arterial glucose level is not the reference site for generation of the portal signal in conscious dogs.

P S Hsieh1, M C Moore, B Marshall, M J Pagliassotti, B Shay, D Szurkus, D W Neal, A D Cherrington.   

Abstract

Experiments were performed on twelve 42-h-fasted, conscious dogs to determine whether the head arterial glucose level is used as a reference standard for comparison with the portal glucose level in bringing about the stimulatory effect of portal glucose delivery on net hepatic glucose uptake (NHGU). Each experiment consisted of an 80-min equilibration, a 40-min control, and two 90-min test periods. After the control period, somatostatin was given along with insulin (7.2 pmol. kg(-1). min(-1); 3.5-fold increase) and glucagon (0.6 ng. kg(-1). min(-1); basal) intraportally. Glucose was infused intraportally (22.2 micromol. kg(-1). min(-1)) and peripherally as needed to double the hepatic glucose load. In one test period, glucose was infused into both vertebral and carotid arteries (HEAD(G); 22.2 +/- 0.8 micromol. kg(-1). min(-1)); in the other test period, saline was infused into the head arteries (HEAD(S)). One-half of the dogs received HEAD(G) first. When all dogs are considered, the blood arterial-portal glucose gradients (-0.52 +/- 0.07 vs. -0.49 +/- 0.03 mM) and the hepatic glucose loads (339 +/- 14 vs. 334 +/- 20 micromol. kg(-1). min(-1)) were similar in HEAD(G) and HEAD(S). NHGU was 24.1 +/- 3.8 and 25.1 +/- 4.6 micromol. kg(-1). min(-1), and nonhepatic glucose uptake was 46.1 +/- 4.2 and 48.8 +/- 7.0 micromol. kg(-1). min(-1) in HEAD(G) and HEAD(S), respectively. The head arterial glucose level is not the reference standard used for comparison with the portal glucose level in the generation of the portal signal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516127     DOI: 10.1152/ajpendo.1999.277.4.E678

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  3 in total

Review 1.  Regulation of hepatic glucose uptake and storage in vivo.

Authors:  Mary Courtney Moore; Katie C Coate; Jason J Winnick; Zhibo An; Alan D Cherrington
Journal:  Adv Nutr       Date:  2012-05-01       Impact factor: 8.701

2.  Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.

Authors:  Dale S Edgerton; Melanie Scott; Ben Farmer; Phillip E Williams; Peter Madsen; Thomas Kjeldsen; Christian L Brand; Christian Fledelius; Erica Nishimura; Alan D Cherrington
Journal:  JCI Insight       Date:  2019-02-26

3.  Enterically delivered insulin tregopil exhibits rapid absorption characteristics and a pharmacodynamic effect similar to human insulin in conscious dogs.

Authors:  Justin M Gregory; Margaret Lautz; Lindsey M Moore; Phillip E Williams; Praveen Reddy; Alan D Cherrington
Journal:  Diabetes Obes Metab       Date:  2018-09-16       Impact factor: 6.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.